Know Where Ubrelvy Fits for Acute Migraine Treatment
February 2023
Ubrelvy (ubrogepant) will be the first oral CGRP antagonist to TREAT acute migraine in adults.
Ubrelvy is a “gepant.” It blocks receptors of calcitonin gene-related peptide (CGRP), a vasodilator and pain sensitizer that spikes during migraine attacks.
It’s different than the injectables for PREVENTION (Aimovig, Ajovy, Emgality, Vyepti)...these are monoclonal antibodies that block CGRP effects.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive